New combo aims to tackle tough prostate cancer

NCT ID NCT04109729

Ongoing Disease control Sponsor: University of Utah Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests two drugs together—nivolumab (Opdivo) and Radium-223 (Xofigo)—in 39 men with metastatic castration-resistant prostate cancer that has spread to the bones. The main goals are to check safety and see if the combination can reduce tumor DNA in the blood. It is not yet known if this approach will work better than current treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab (Opdivo) and Radium-223 (Xofigo)
What this could lead to: If it works, this could point toward a new combination treatment for advanced prostate cancer that has spread to the bones.
What could go wrong: This is a very early phase 1 trial with only 39 men, so it is primarily checking safety and dosing. The combination may cause serious side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Huntsman Cancer Institute at University of Utah

Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.